WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006120456) PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/120456    International Application No.:    PCT/GB2006/001737
Publication Date: 16.11.2006 International Filing Date: 11.05.2006
IPC:
A61K 31/18 (2006.01), A61K 47/40 (2006.01), A61K 47/18 (2006.01), A61K 47/26 (2006.01), A61P 35/00 (2006.01)
Applicants: TOPOTARGET UK LIMITED [GB/GB]; 87A Milton Park, Abingdon Oxfordshire OX14 4RY (GB) (For All Designated States Except US).
BASTIN, Richard, J. [GB/IE]; (IE) (For US Only).
HUGHES, Nicholas, J. [GB/GB]; (GB) (For US Only)
Inventors: BASTIN, Richard, J.; (IE).
HUGHES, Nicholas, J.; (GB)
Agent: WYTENBURG, Wilhelmus; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB)
Priority Data:
60/681,215 13.05.2005 US
60/681,234 13.05.2005 US
Title (EN) PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS
(FR) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE HDAC
Abstract: front page image
(EN)This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
(FR)L'invention concerne des compositions pharmaceutiques comprenant certains composés à base d'acide carbamique (p. ex., ceux qui inhibent l'activité de HDAC (histone désacétylase)) (p.ex., PXD-101, N hydroxy-3-(3-phénylsulfamoyl-phényl)-acrylamide)) et un ou plusieurs ingrédients sélectionnés parmi cyclodextrine, arginine et méglumine. La présente invention concerne aussi l'utilisation de ces composés, par exemple, dans l'inhibition de HDAC et dans le traitement d'états à médiation par HDAC, du cancer, des états proliférants, du psoriasis, etc.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)